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Abstract
Multiple Sclerosis (MS) affects 400,000 people in
the USA and almost 2.5 million people worldwide.
There is no cure for MS. A variety of disease-modifying
therapies are currently available. They aim to reduce
disease activity that ultimately leads to disability.
However, such drugs have adverse effects that vary
widely among patients making the choice of a suitable
drug particularly challenging. With the proliferation of
social media, this research aims to understand the
perspective of people with MS on social media (Twitter)
in regard to Adverse Drug Events (ADEs) and to
analyze ADEs as perceived by MS patients. This study
helps in understanding ADEs associated with MS drugs
and can further inform future medical research by
highlighting and prioritizing additional clinical trials
needed to better assess such adverse drug effects.

1. Introduction
Multiple Sclerosis (MS) is considered to be an
immune-meditated disease that occurs when the
immune system attacks the central nervous system
(CNS). The immune system’s attack damages myelin,
oligodendrocytes, and underlying nerve fibers,
impairing the ability of the CNS to send or receive
messages [1]. The most unsettling aspect of MS is that
its cause is still not clear. Based on the clinical criteria,
frequency of clinical relapses, time taken for disease
progression, and lesion development as shown by MRI
findings, MS is classified into four types, namely
Relapsing-remitting
MS
(RRMS),
Secondary
Progressive MS (SPMS), Primary progressive MS
(PPMS) and Clinically Isolated Syndrome (CIS).
Almost 85% of people having MS fall under RRMS,
which is characterized by relapses followed by periods
of complete or partial recovery [2]. Some early signs
and symptoms of MS include tingling and numbness,
optic neuritis, fatigue, pain, muscle spasm and
weakness, balance problems, bladder issues, cognitive

difficulties, depression, and anxiety. MS patients are
prescribed disease-modifying drugs to delay
neurological disability progression [3], [4].
ADEs are unfavorable and unintentional signs or
symptoms associated with the use of a medication [5].
The Center for Disease Control (CDC) advises adults to
follow precautions to reduce the risk of ADEs by
keeping a list of their medications, following directions,
asking questions, keeping up with any blood testing
recommended by the doctor, and taking all the
medicines strictly as directed. The burden of ADEs to
the nation’s economy is estimated at $30.1 billion
annually [6]. Prescription drugs for MS are known to
result in a variety of adverse effects, some of which are
very serious. While many of these adverse effects are
reported in the literature, their extent varies substantially
among MS patients making it particularly challenging
to identify a suitable drug for a particular patient. This
is also a recurring problem as patients often need to
switch medications during the course of treatment.
With the proliferation of social media, health
became a prevalent topic that people discuss on these
platforms [7]. Today, social media has evolved as a
fertile platform for patients to exchange information
regarding their experiences with a life-changing
condition such as MS. This includes sharing information
about symptoms, disease progression, and adverse drug
effects. Such wealth of information creates
opportunities for healthcare professionals and
researchers to gain further insights into various disease
conditions as they relate to symptoms, adverse drug
effects and experiences.
A few studies have proposed ADE detection
methods utilizing social media data [8]. These social
media platforms can be patient discussion forums or
social networking platforms such as Facebook and
Twitter. To the best of our knowledge, there are only
two studies that utilized social media data for assessing
patterns and sentiments regarding MS treatments. One
exploratory study investigated opinions regarding MS

treatments and found that oral MS treatments tend to
show higher sentiment scores than injectable treatments
[9], while another study explored patterns of treatment
switching by MS patients [10].
Accordingly, in this research, we complement prior
research by extracting prevalent MS ADEs as reported
on social media (Twitter). Further, we conduct a
sentiment analysis that provides a holistic perspective of
patients’ perception of various drugs given their side
effects. The analysis covers 18 different MS drugs and
leverages text mining to quantify the volume and
sentiments of the ensuing discussion, and to capture the
dominant ADEs categories for each drug. Overall, this
sheds light on the safety and effectiveness of drugs used
for MS treatment. The outcome can help patients and
clinicians identify appropriate courses of action.
Further, the results can inform future medical research
by highlighting and prioritizing additional clinical trials
needed to better understand such adverse drug effects.
The remainder of the paper is organized as follows:
Section 2 provides a brief review of related work while
section 3 describes the research methodology. Section 4
presents the results obtained while section 5 includes an
interpretation and discussion of our findings with
reference to extant research. Section 6 concludes by
summarizing the research and discussing the limitations
and research scope for the future.

2. Related work
ADEs post-marketing surveillance can rely on
different types of data obtained from various sources
[11] such as Electronic Health Records (EHR), and
voluntarily reported data on such systems as the Food
and Drug Administration’s (FDA) Adverse Event
Reporting System (FAERS) [12]. However, these
sources could suffer from low reporting rates and
limited scope. Accordingly, a number of studies utilized
social media platforms as a source potentially offering a
relatively broad and timely data to understand and
address health-related issues [13], [14]. Of particular
interest to the medical informatics research community
is leveraging social medial to monitor ADEs [8]. For
example, a few studies [15]–[18] used Twitter to detect
and track ADEs while other studies relied on healthcare
social media forums [19], [20]. Some studies on ADEs
proposed and implemented near real-time pipelines and
models for ADE detection and prediction [18], [21].
ADEs studies utilized a variety of techniques such as but
not limited to; association rule mining [20], natural
language processing (NLP) and deep learning [22],
extracting deep linguistic features [23], ensemble
classification [24], statistical modeling [25], and topic
modeling.

With respect to MS, one study used an exploratory
approach to analyze sentiments pertaining to MS
treatments using twitter data [9]. The study identified
tweets mentioning MS treatments and used them to
analyze patients’ sentiments. The study conducted in
2014 did not analyze adverse effects nor did it include a
number of now available newer medications. Another
study used automated listening with filtering and
analysis of data to examine the patterns of treatment
switching between infectable, oral, and infusion
therapies for MS patients [10]. Accordingly, this study,
complement prior research by focusing on the ADEs of
MS treatments from user contributed contents, namely
Twitter, as well as further exploring patients’ sentiments
towards MS medications on a wider selection of these
drugs.

3. Methodology
We followed the pipeline in Figure 1 for performing
this research. The pipeline included four stages: data
discovery, data collection, data preparation, and data
analysis. We employed Crimson Hexagon (CH) (now
Brandwatch) to understand the public’s perspective on
MS treatments and ADEs. CH is an AI-powered
consumer insights tool used to scrape data from social
media and analyze it for insights. It is a social media
analytics tool that utilizes machine learning and text
mining approaches developed by the founder of CH
[26].

Figure 1. ADE detection pipeline

The Data discovery stage consisted of creating a
Boolean search query for CH using the drug names. The
search query was limited to tweets in the English
language, from 1 Jan 2010 to 1 Jan 2020. The MS
treatments considered for this study were Avonex,
Betaseron, Copaxone, Glatiramer Acetate, Extavia,
Glatopa, Plegridy, Rebif, Aubagio, Gilenya,
Mavenclad, Mayzent, Tecfidera, Vumerity, Lemtrada,
Novantrone, Ocrevus, and Tysabri. We standardized the
search based on the brand names of the drugs, as some
of the active ingredients (generic name) are indicated for
other conditions. CH search query employed case
insensitive approach for searching the tweets.
In the data collection stage, the search query
retrieved the required data from CH for manual
examination for relevant posts. The retrieved data for all
the drugs was examined particularly for unusually high
volume of tweets on a particular day or time period to
help us redefine the inclusion and exclusion criteria in
the data discovery stage. This examination of tweets was
manually done. Overall, we found that there was quite
an unusual activity due to retweets. Further, tweets
containing hyperlinks were considered to be irrelevant
as they often link to advertisement or news articles about
a particular medication rather than the patients’
experience. Tweets with a stock market symbols of
pharmaceutical companies were excluded. Ultimately,
we developed the search query template shown below:

is to categorize the posts into a pre-defined number of
categories and calculate the proportion of posts in each
category [26]. This provides unbiased categorization
and proportions even when the customized classifier
performs poorly.

4. Results
A total of 51,362 unique tweets mentioned MS
treatments after removing the tweets containing
manufacturer or company names and hyperlinks.
Overall, 16% of the tweets included age identification,
while 65% identified gender. The available
demographics of tweets are shown in Figure 2.

Figure 2a. Distribution of tweets by age group

(“Drug Brand Name 1” OR “Drug Brand Name 2”
OR “Drug Brand Name 3” OR ………….)
AND – (http* OR RT)
AND – (Merck OR Sereno OR Pfizer OR Biogen
OR Bayer OR Novartis OR Teva OR Momenta OR
Sandoz OR Sanofi OR Genentech OR "Roche
Group")

Search queries for some drugs had to be customized
based on examining the tweets related to the drugs
respectively. For example, we found a Twitter handle
named ‘@aubagio’. However, there was no relation to
MS for tweets coming from this handle.
Once the finalized query was run in CH, we
proceeded to the data analysis stage. We analyzed the
results for each drug tweets by excluding references to
other drugs to make sure each tweet reflects only one
medication. Although some tweets comparing different
medications would be lost, it was the best way to make
sure we performed a valid analysis on each drug. We
analyzed the sentiments and emotions towards MS
treatment using the pre-trained classifier in CH. We
employed the ReadMe algorithm [26] to analyze the
posts that fall into predefined categories representing
various adverse drug effects. The MS ADEs predefined
categories follow the list of common side effects defined
by the National MS Society for each drug. The ReadMe
algorithm is appropriate when the objective of the study

Figure 2b. Distribution of tweets by gender
We utilized pre-trained sentiment categories
(Positive, Negative and Neutral) in CH to detect a
tweet’s sentiment and categorize it into one of the
sentiment categories. Similarly, we employed the predefined emotion categories (Joy, Sadness, Disgust,
Anger, Surprise, Fear and Neutral) in CH to classify the
posts into one of the emotion categories. Figure 3 shows
the sentiment and emotion proportions of the tweets for
all drugs. At the same time, the emotion analysis shows
that 37% of the tweets are neutral and followed by Joy,
Anger, Fear, Sadness, Disgust and Surprise.
Table 1 illustrates the tweet distribution for each
drug, along with the sentiment proportions. With
exclusion criteria refers to searching for a particular
drug and excluding reference to all other drug names,
while without exclusion criteria refer to searching for a
particular drug and not excluding reference to all other
drug names. Overall, the sentiment proportions for
tweets with and without exclusion criteria were

approximately very similar. Extavia and Tysabri had the
highest positive sentiment proportion. Rebif and
Avonex had the highest negative sentiment proportion.
Copaxone, Ocrevus, Tysabri, Lemtrada, Plegridy,
Gilenya, Mayzent and Extavia had slightly more
positive sentiments than negative.

Figure 3. Sentiment and emotion distribution
of tweets

Figure 4 depicts the distribution of tweets over time
for MS treatments. The distribution results are similar to
the study by Ramagopalan et al. [9] for that specific time
period. The relative proportion of the adverse effects for
each drug is shown in Figure 5. Adverse events for
Avonex, Betaseron, Extavia, Rebif, and Plegridy were
quite similar, as these medications have the same active
ingredient, “Interferon Beta”. More than 50% of
Aubagio’s side effects were attributed to diarrhea, hair
loss/thinning, and liver problems. More than 61% of
Copaxone side effects were attributed to injection site
problems and shortness of breath.
Liver problems alone contributed to 45% of
Gilenya’s side effects. Liver problems, low white blood
cells, and flu/fever/body aches accounted for 68% of
interferon-beta’s side effects. Headache, rashes, and
kidney problems contributed to 64% of the Lemtrada’s
side effects. Mavenclad’s side effects were mostly
attributed to hair loss/thinning (30%), low white blood
cell count (25%), mouth sores and/or shingles (25%),
and rashes (21%). Headache and low heart rate
constituted 58% of Mayzent’s side effects. Novantrone
side effects were caused by skin rash/reactions (75%),
and infections (25%). Ocrevus’s side effects were
mainly itchy skin (40%), rash (33%), and throat
irritation (27%). Hot flushes and nausea contributed to
65% of Tecfidera’s side effects. Headache and dizziness
contributed to 56% of Tysabri’s side effects.

Table 1. Distribution of Tweets Data for Each Drug

Aubagio
Avonex
Betaseron
Copaxone
Extavia
Gilenya
Lemtrada
Mavenclad
Mayzent
Novantrone
Ocrevus
Plegridy
Rebif
Tecfidera
Tysabri
Vumerity
Total

# of Tweets
(with
Exclusion
Criteria)

# of Tweets
(without
Exclusion
Criteria)

1,156
3,945
910
8,733
265
5,007
3,512
234
41
79
2,430
333
4,376
4,881
10,760
15
46,677

1,526
5,099
1,303
10,421
324
5,969
4,009
293
53
105
2,912
450
5,383
5,958
12,365
24
56,194

Proportions of tweet sentiments
(with exclusion criteria)

Proportions of tweet sentiments
(without exclusion criteria)

Positive

Negative

Neutral

Positive

Negative

Neutral

0.282
0.340
0.245
0.340
0.668
0.315
0.374
0.345
0.300
0.105
0.364
0.333
0.318
0.338
0.430
0.200

0.358
0.361
0.325
0.330
0.112
0.255
0.306
0.345
0.250
0.235
0.326
0.297
0.372
0.352
0.310
0.200

0.360
0.300
0.430
0.330
0.220
0.430
0.320
0.310
0.450
0.660
0.310
0.370
0.310
0.310
0.260
0.600

0.280
0.333
0.259
0.342
0.595
0.319
0.368
0.363
0.348
0.146
0.362
0.314
0.321
0.337
0.419
0.220

0.371
0.367
0.331
0.348
0.155
0.281
0.312
0.337
0.212
0.264
0.338
0.316
0.379
0.363
0.321
0.220

0.350
0.300
0.410
0.310
0.250
0.400
0.320
0.300
0.440
0.590
0.300
0.370
0.300
0.300
0.260
0.560

Figure 4. Distribution of tweets over time for each treatment

Figure 5. Tweet classification of ADEs for each treatment (with exclusion criteria)

5. Discussion
Based on the available demographics shown in
Figure 2, women tweeted more about MS treatments
compared to men. People who were older than 35
years tweeted more compared to other age groups.
According to the National Multiple Sclerosis Society,
MS is three time more common among women and
most patients are diagnosed between the ages of 20
and 50 years [27].
The sentiment analysis in this study is consistent
with Ramagopalan et al. [9]. The findings of the
discovered sentiment scores from Table 1 show that
treatments such as Extavia, Gilenya, Lemtrada,
Mayzent, Ocrevus, and Tysabri have higher positive
than negative tweet proportions. Extavia is the only
injectable treatment in this category. Lemtrada,
Tysabri, and Ocrevus are infusion treatments, while
Gilenya and Mayzent are oral treatments. Mavenclad
and Tecfidera, both oral treatments, appear to have a
neutral sentiment among the public. Vumerity is new
to the market and limited data is available for it. Based
on the tweets and sentiment analysis, Aubagio, an oral
drug, has a substantial negative sentiment due to the
side effects associated with it.
With respect to the distribution of tweets over
time (figure 4), the tweets volume for each treatment
shows spikes at various time points. Further
investigation into the Twitter corpus revealed that
spikes in the tweet volume coincide with news
regarding the FDA approval of new MS drugs. Each
treatment’s sentiment scores clearly show a positive
intent and excitement for newer treatments that hit the
market. Most of the treatments have word clusters
related to social support and symptoms associated with
the treatments. For instance, the word clusters for
Extavia have “Cost” as the frequent word, and the
other words in the clusters are “iPhone” and related
terms. When the tweet corpus for Extavia was further
investigated, it revealed an interesting story: people
compare the cost of Extavia treatment to that of iPhone
revealing the public discourse on the soaring cost of
MS drugs. The finding is in accordance with an
existing concern over the high pricing of MS specialty
medications [28], [29].
To the best of our knowledge, we present here the
first analysis on the proportion of ADEs for each MS
treatment. The discovered symptoms and ADEs are
mapped to the valence of tweets for each treatment as
summarized in Figure 5. Adverse events for Avonex,
Betaseron, Extavia, Rebif, and Plegridy were quite
similar, as these medications have the same active
ingredient, “Interferon Beta”. Liver problems, low
white blood cells, and flu/fever/body aches

contributed to 68% of interferon-beta’s side effects.
Nearly two-thirds (61%) of Copaxone’s side effects
were caused by injection-site reactions and shortness
of breath. The findings are generally consistent with
the listed side effects [30] for this group of
medications. Although flu-like symptoms and
injection-site reactions are listed among the most
common side effects [31] for interferon- beta, they
made up only 17% and 9% respectively of discussed
ADEs. One explanation is that patients focused on the
more serious side effect of liver problems (34%) in
their tweets.
In the oral medication group, slightly more than
half (51%) of Aubagio’s side effects were attributed to
diarrhea, hair loss/thinning, and liver problems. Liver
problems alone accounted for nearly half (45%) of
Gilenya’s side effects. Hot flushes and nausea
contributed to 65% of Tecfidera’s side effects.
Mavenclad side effects were primarily attributed to
hair loss/thinning (30%), low white blood cell count
(25%), mouth sores and/or shingles (25%), and rashes
(21%). Headache and low heart rate constituted 58%
of Mayzent’s side effects. The findings for the oral
group were mostly consistent with the listed side
effects of the included medications [30]. However,
Mavenclad, an oral immunosuppressant that is
generally indicated to patients who have had an
inadequate response or could not tolerate one or more
MS therapies, had markedly fewer discussed ADEs as
compared to the listed side effects [32], [33]. This can
be explained by the recent FDA approval for the
medication as well as its being a less commonly
prescribed one, which could have affected data
availability.
In the infusion medications group, headache,
rashes, and kidney problems contributed to 64% of
Lemtrada’s side effects. Novantrone side effects were
caused by skin rash/reactions (75%), and infections
(25%). Ocrevus’s side effects were mainly itchy skin
(40%), rash (33%), and throat irritation (27%).
Headache and dizziness contributed to 56% of
Tysabri’s side effects. The adverse events such as
Progressive multifocal leukoencephalopathy (PML)
are discussed in tweets related to Tysabri. Most of the
tweets that talk about PML usually discuss the risk of
a dangerous brain infection, contributing to fear and
panic. The risk of PML with Tysabri can be addressed
by the implementation of a risk management plan
(RMP) [34]. The findings for the infusion medications
were mostly consistent with the listed side effects
except for Novantrone. Its most common listed side
effects include nausea and hair thinning, yet our
findings show skin rash/reactions to account for 75%
of discussed ADEs. It is important to note that the risk
of cardiac toxicity posed by this medication shadows

the decision for its potential use [35]. Together with a
recent discontinuation of the brand-name medication
and its availability under the generic name
mitoxantrone , this may explain the data limitation
[36].
Most MS patients will initially be on first-line
injectable treatments, which tend to have mild and
manageable ADEs. [37]. However, the effectiveness
of such medications and the patient’s tolerance of the
side effects may warrant a switch to other treatments
[10]. Based on the course of MS and individual
patient’s response, second-line or third-line
medications may be selected. The ADEs identified in
this study for each treatment is consistent with the
National Multiple Sclerosis Society’s comparisons of
different drugs and their ADEs [38].
This study emphasizes the significance of further
adoption of text mining techniques for detecting
adverse drug events. Multiple sclerosis is not common
but is a serious cause of neurological disability
throughout adult life. Its prevalence has seen a marked
increase since 1990 [39]. From a practical standpoint,
automatically analyzing social media users posting
with machine learning techniques will provide the
medical community with valuable insights on patients’
behavior and reaction towards ADEs, symptoms, and
treatments associated with MS. These may aid in
recognizing the current state of MS treatments and the
ADEs associated with it and can improve healthcare
providers' understanding of the commonness of a
particular ADE associated with an MS treatment as
reported by patients.

6. Conclusion
This research focused on the ADEs of MS
treatments from user-contributed contents on social
media. The sentiment analysis and categorization of
ADEs for various MS treatments indicate that the
discussed side effects for injectable medications
(Interferon-beta (Avonex, Betaseron, Extavia,
Plegridy and Rebif), and Copaxone) are slightly higher
when compared to infusion or oral medications. The
underlying reasons for patients’ dislike of injectable
medications are the side effects caused by the injection
itself (frequent use of needles, injection-site reactions,
and rashes). Furthermore, there is a noticeable
excitement for new treatments such as Vumerity,
Mavenclad, and Mayzent. Overall, the results shed
light on the safety and effectiveness of drugs used for
MS treatment and complement other post-marketing
surveillance
conducted
through
centralized
volunteering reporting systems by relying on a
relatively broader and timely user-contributed data.
The results and recommendations of this study can

help patients and clinicians identify appropriate
courses of action and can inform future medical
research by highlighting and prioritizing additional
clinical trials needed to better understand such adverse
drug effects.
Some limitations of this study include constraints
related to the data, namely, language (English), data
source (Twitter), and analytics techniques. Twitter
data might not reflect the actual patient population.
According to Wojcik and Hughes [40], Twitter users
tend to be a much younger audience, with 10% of users
creating 80% of all tweets published. Future research
may consider expanding to other languages and social
media platforms such as health-related forums, Reddit,
and Facebook. While CH provides extensive analytic
and visualization capabilities, it may be limiting with
respect to the diversity and complexity of the available
techniques. For example, other machine learning such
as topic mining coupled with thematic content analysis
based on demographics and ADE type may shed
further insights regarding the ADEs of various MS
treatments.
MS, a progressive degenerative disease of the
central nervous system, has yet no cure. Current
treatment options aim to reduce the contributory
immune system’s attacks thereby reducing the number
of relapses and slowing the progression of disability.
Different oral, injectable, and infusion drugs for the
disease are available with more drugs being introduced
to the market. As MS treatment is long-term, ADEs
present a challenge that affects the choice of drugs and
the decision to remain on a given drug or change to
another. As a result, the thorough understanding of
these ADEs will be an ongoing endeavor.
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